Lenalidomide treatment of chronic lymphocytic leukaemia patients reduces regulatory T cells and induces Th17 T helper cells.
Idler
Irina
I
Giannopoulos
Krzysztof
K
Zenz
Thorsten
T
Bhattacharya
Nupur
N
Nothing
Maria
M
Döhner
Hartmut
H
Stilgenbauer
Stephan
S
Mertens
Daniel
D
D000970:Antineoplastic Agents / Q000494:pharmacology*; D006801:Humans; D020381:Interleukin-17 / Q000032:analysis; D000077269:Lenalidomide; D015451:Leukemia, Lymphocytic, Chronic, B-Cell / Q000276:immunology*; D006377:T-Lymphocytes, Helper-Inducer / Q000187:drug effects*; D050378:T-Lymphocytes, Regulatory / Q000187:drug effects*; D013792:Thalidomide / Q000031:analogs & derivatives* / Q000494:pharmacology
D000970:Antineoplastic Agents; D020381:Interleukin-17; D013792:Thalidomide; D000077269:Lenalidomide